None listed
Conditions
Interventions
Drug : This study investigates the optimal effect-site concentration (Ce) of remifentanil required to maintain hemodynamic stability during double-lumen tube (DLT) intubation and fiberoptic bronchosco
Sponsors
Samsung Changwon Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adult patients aged 19 to 64 years. Patients scheduled for elective surgery requiring general anesthesia with double-lumen tube intubation and fiberoptic bronchoscopy. Patients with an American Society of Anesthesiologists (ASA) physical status of I ~III Patients who have provided voluntary written informed consent after receiving a detailed explanation of the study.
Exclusion criteria
Exclusion criteria: Patients with an anticipated difficult intubation. Patients with psychiatric disorders resulting in impaired decision-making or communication skills. Patients with cognitive impairment. Patients with heart failure or a history of myocardial infarction within the past 6 months. Patients with severe arrhythmia. Patients with severe pulmonary disease. Patients with a history of hypersensitivity to remimazolam or remifentanil. Pregnant or lactating women. Any other patients deemed inappropriate for study participation by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maintenance of hemodynamic stability during double-lumen tube (DLT) intubation and fiberoptic bronchoscopy | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in mean arterial pressure (MAP) and heart rate (HR);Incidence of hemodynamic adverse events (ehypotension, bradycardia, hypertension, tachycardia) and the use of rescue medications (ephedrine, atropine, nicardipine, esmolol, phenyleprine);Incidence and severity score of cough and somatic movement during intubation and bronchoscopy manipulation | — |
Countries
Korea, Republic of
Contacts
Public ContactSungae Cho
Samsung Changwon Medical Center
Outcome results
None listed